CEREVEL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Cerevel Therapeutics Holdings, Inc. (CERE) Buyout and Encourages Investors to Contact the Firm
Cerevel Therapeutics Holdings, Inc. (CERE)
Company Research
Source: GlobeNewswire
PHILADELPHIA, April 30, 2024 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) (“Cerevel”) on behalf of the company’s investors. On December 6, 2023, Cerevel announced that it had agreed to be acquired by AbbVie Inc. at a price of $45.00 per share in cash. Following the closing of the proposed transaction, Cerevel’s current stockholders will be cashed out of their investment position and the company’s shares will no longer be publicly traded. The investigation seeks to determine whether Cerevel shareholders are set to receive sufficient consideration for their shares, and whether Cerevel’s officers and/or directors breached their fiduciary duties or violated the securities laws in agreeing to sell the company at $45.00 per share to AbbVie. Cerevel shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (888) 715 – 1740 or (484) 229 – 0750, or by email (skaske
Show less
Read more
Impact Snapshot
Event Time:
CERE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CERE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CERE alerts
High impacting Cerevel Therapeutics Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
CERE
News
- BREAKING CEREVEL INVESTIGATION: BFA Law Is Investigating the $45 Per CERE (Nasdaq) Share Offer by AbbVie, Contact the Firm for DetailsGlobeNewswire
- 1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165? [Yahoo! Finance]Yahoo! Finance
- NOTICE OF INVESTIGATION: Kaskela Law LLC Announces Shareholder Investigation of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) and Encourages Investors to Contact the FirmPR Newswire
- INVESTIGATION ANNOUNCEMENT: BFA Law Announces an Ongoing Investigation into the Merger between Cerevel Therapeutics and AbbVie for Unfair ProcessGlobeNewswire
- ACQUISITION ALERT BFA LLP Notifies Cerevel Therapeutics Shareholders of an Investigation into the Merger with AbbVieAccesswire
CERE
Earnings
- 5/8/24 - Miss
CERE
Sec Filings
- 5/14/24 - Form 4
- 5/10/24 - Form 144
- 5/10/24 - Form SC
- CERE's page on the SEC website